Læknablaðið - 15.09.1994, Síða 50

320
LÆKNABLAÐIÐ 1994; 80
Table II. Clinical and laboratory assessments of 60 patients with PUD.
Assessments Triple therapy initiated Months after triple therapy
1 month 3 months 6 months 12 months
Symptoms X X X X X
Physical examination X X X X X
Endoscopy X X X X X
Antral biopsy X X X X X
CLO- test X X X X X
Laboratory screen X X X
PUD: peptic ulcer disease
Table III. Comparison between patients in DMA and DMT group.
Medication Number Sex (M/F) Age (mean) GU/DU History (yrs) Smoker %
DMA 30 7/23 51.7 5/25 16.2 14 (46)
DMT 30 12/18 55.2 5/25 16.3 17 (56)
p value 0.27 0.23 0.96 0.61
M: male F: female GU: gastric ulcer DU: duodenal ulcer DMA: DeNol, metronidazole, ampicillin
DMT: DeNol, metronidazole, tetracyclin
Table IV. One monlh follow up of 60 PUD patients.
H. pylori status DMA (%) DMT (%) Total (%)
H.pylori - ve 24 (80) 30 (100)* 54 (90)
H.pylori +ve 6 (20) 0 ( 0) 6 (10)
*p=0.024
PUD: peptic ulcer disease DMA: DeNol, metronidazole, ampicillin
DMT: DeNol, metronidazole, tetracyclin
Table V. 12 month follow up of 60 PUD patients.
H. pylori status DMA (%) DMT (%) Total (%)
H.pylori - ve 23 (77) 30 (100)* 53 (88)
H.pylori +ve 7 (23) 0 ( 0) 7 (12)
*p=0.0105
PUD: peptic ulcer disease DMA: DeNol, metronidazole, ampicillin
DMT: DeNol, metronidazole, tetracyclin
Table VI. Severe side effects in 60 patients during triple therapy.
Medication Allergic reactions (%) Diarrhea (%) Suprainfection (%> Total* (%)
DMA (30) 0 1 (3) 0 1 (3)
DMT (30) 2 (7) 2 (7) 1 (3) 5 (17)
Total (60) 2 (3) 3 (5) 1 (2) 6 (10)
* p=0.17
DMA: DeNol, metronidazole, ampicillin DMT: DeNol, metronidazole, tetracyclin